| Nov 21 |
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
|
| Nov 8 |
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
|
| Nov 7 |
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates
|
| Nov 6 |
uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 5 |
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 5 |
UniQure: Q3 Earnings Snapshot
|
| Nov 5 |
uniQure GAAP EPS of -$0.91 beats by $0.03, revenue of $2.29M misses by $4.77M
|
| Nov 5 |
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
|
| Oct 30 |
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
|
| Oct 29 |
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
